Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Langer

Showing results (31-40 of 686) with videos related to

Pageof 69
Sort By:
Cancer|April 30, 2008
Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applicationsCorey J Langer
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2009
The "lazarus response" in treatment-naive, poor performance status patients with non-small-cell lung cancer and epidermal growth factor receptor mutationCorey J Langer
Clinical Lung Cancer|January 15, 2004
The emerging role of gemcitabine in combination with radiation in locally advanced, unresectable non-small-cell lung cancerCorey J Langer
Seminars in Radiation Oncology|April 21, 1999
Concurrent chemoradiation using paclitaxel and carboplatin in locally advanced non-small cell lung cancerC J Langer
Investigational New Drugs|June 1, 2000
Advanced non-small cell lung carcinoma: the emerging role of docetaxelC J Langer
Lung Cancer (Amsterdam, Netherlands)|October 27, 2001
The role of UFT and the combination of UFT/leucovorin in non-small cell lung cancerC J Langer
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2001
Does salvage therapy influence outcome?C J Langer
Expert Review of Anticancer Therapy|August 26, 2003
Role of targeted therapy in non-small cell lung cancer: hype or hope?Corey J Langer
Oncology (Williston Park, N.Y.)|July 31, 2003
The global role of irinotecan in the treatment of lung cancer: 2003 updateCorey J Langer
Clinical Lung Cancer|January 11, 2005
CT-2103: a novel macromolecular taxane with potential advantages compared with conventional taxanesCorey J Langer
Pageof 69

Showing results (31-40 of 686) with videos related to

Sort By:
Pageof 69
Cancer|April 30, 2008
Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applicationsCorey J Langer
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2009
The "lazarus response" in treatment-naive, poor performance status patients with non-small-cell lung cancer and epidermal growth factor receptor mutationCorey J Langer
Clinical Lung Cancer|January 15, 2004
The emerging role of gemcitabine in combination with radiation in locally advanced, unresectable non-small-cell lung cancerCorey J Langer
Seminars in Radiation Oncology|April 21, 1999
Concurrent chemoradiation using paclitaxel and carboplatin in locally advanced non-small cell lung cancerC J Langer
Investigational New Drugs|June 1, 2000
Advanced non-small cell lung carcinoma: the emerging role of docetaxelC J Langer
Lung Cancer (Amsterdam, Netherlands)|October 27, 2001
The role of UFT and the combination of UFT/leucovorin in non-small cell lung cancerC J Langer
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2001
Does salvage therapy influence outcome?C J Langer
Expert Review of Anticancer Therapy|August 26, 2003
Role of targeted therapy in non-small cell lung cancer: hype or hope?Corey J Langer
Oncology (Williston Park, N.Y.)|July 31, 2003
The global role of irinotecan in the treatment of lung cancer: 2003 updateCorey J Langer
Clinical Lung Cancer|January 11, 2005
CT-2103: a novel macromolecular taxane with potential advantages compared with conventional taxanesCorey J Langer
Pageof 69